Literature DB >> 8548871

Integrin expression in non-small cell carcinoma of the lung.

W R Smythe1, E LeBel, J E Bavaria, L R Kaiser, S M Albelda.   

Abstract

Alteration of integrin expression in a number of different malignant diseases has been recognized, with a trend of downregulation of collagen-laminin binding integrin expression in epithelial tumor types noted. This study evaluated the expression of a panel of integrin subunits that included subunits that form receptors that bind to collagen and laminin (alpha 2, alpha 3, alpha 6 beta 4) and subunits that form receptors that bind to fibronectin and fibrinogen (alpha 5, alpha V, beta 3, beta 6) in 51 specimens of non-small cell carcinoma (NSCCA) of the lung by use of immunohistochemistry. Integrin expression was then correlated with histologic type (squamous vs. adenocarcinoma), absence or presence of hilar or mediastinal nodal metastasis at resection, and cellular differentiation (well or poorly differentiated). In general, downregulation of the collagen-laminin binding subunits was noted in tumor cells of the NSCCA specimens when compared to the progenitor normal bronchial epithelium. No differences were noted in integrin expression between squamous cell and adenocarcinoma or between node-positive or node-negative tumors. However, downregulation of the integrin subunit alpha 3 was noted to be significantly more common in poorly differentiated tumors (p = 0.02) and several of the other collagen-laminin binding subunits also appeared to be more downregulated in poorly differentiated tumors. No upregulation was seen in the alpha 5 subunit of the fibronectin receptor or the beta 3 subunit of the vitronectin receptor, however, approximately 50% of tumors showed upregulation of the beta 6 subunit, the great majority of these being well-differentiated, node-negative tumors. Downregulation of the collagen-laminin integrins may thus be associated with differentiation of NSCCA, but not metastasis, and may serve as an adjunctive prognostic marker of disease. The beta 6 subunit appears to be associated with malignant transformation, but may serve as a positive prognostic factor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8548871     DOI: 10.1007/bf00690294

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  39 in total

1.  Integrin cell adhesion molecules and colorectal cancer.

Authors:  M Pignatelli; W F Bodmer
Journal:  J Pathol       Date:  1990-10       Impact factor: 7.996

2.  Identification and characterization of cell-substratum adhesion receptors on cultured human endothelial cells.

Authors:  S M Albelda; M Daise; E M Levine; C A Buck
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

3.  Distribution of VLA integrins in solid tumors. Emergence of tumor-type-related expression. Patterns in carcinomas and sarcomas.

Authors:  M Miettinen; R Castello; E Wayner; R Schwarting
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

4.  Differential expression of alpha 6 and alpha 2 very late antigen integrins in the normal, hyperplastic, and neoplastic prostate: simultaneous demonstration of cell surface receptors and their extracellular ligands.

Authors:  H Bonkhoff; U Stein; K Remberger
Journal:  Hum Pathol       Date:  1993-03       Impact factor: 3.466

5.  Expression of the VLA beta 1 integrin family in bladder cancer.

Authors:  M Liebert; R Washington; J Stein; G Wedemeyer; H B Grossman
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

6.  Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors.

Authors:  M Pignatelli; M R Cardillo; A Hanby; G W Stamp
Journal:  Hum Pathol       Date:  1992-10       Impact factor: 3.466

7.  Involvement of integrin alpha V gene expression in human melanoma tumorigenicity.

Authors:  B Felding-Habermann; B M Mueller; C A Romerdahl; D A Cheresh
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

8.  Loss of alpha 1 beta 1 and reduced expression of other beta 1 integrins and CAM in lung adenocarcinoma compared with pneumocytes.

Authors:  E Roussel; M C Gingras; J Y Ro; C Branch; J A Roth
Journal:  J Surg Oncol       Date:  1994-07       Impact factor: 3.454

9.  Lung cancer.

Authors:  W D Travis; L B Travis; S S Devesa
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

10.  Cancer statistics, 1995.

Authors:  P A Wingo; T Tong; S Bolden
Journal:  CA Cancer J Clin       Date:  1995 Jan-Feb       Impact factor: 508.702

View more
  6 in total

1.  Regulation of keratin and integrin gene expression in cancer and drug resistance.

Authors:  N Daly; P Meleady; D Walsh; M Clynes
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

Review 2.  Molecular imaging of integrin αvβ6 expression in living subjects.

Authors:  Hao Liu; Yue Wu; Fan Wang; Zhaofei Liu
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-06-07

3.  Integrin alpha v beta 3-targeted imaging of lung cancer.

Authors:  Xiaoyuan Chen; Eric Sievers; Yingping Hou; Ryan Park; Michel Tohme; Robert Bart; Ross Bremner; James R Bading; Peter S Conti
Journal:  Neoplasia       Date:  2005-03       Impact factor: 5.715

4.  Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus.

Authors:  M C Boelens; A van den Berg; I Vogelzang; J Wesseling; D S Postma; W Timens; H J M Groen
Journal:  J Clin Pathol       Date:  2006-02-17       Impact factor: 3.411

5.  Transforming growth factor-β1 and lysophosphatidic acid activate integrin β6 gene promoter in Hep-3B cells.

Authors:  Ruirui Xu; Mingyan Xu; Yucai Fu; Xiaoling Deng; Hui Han; Xihe Chen; Wenjing He; Gengzhen Chen
Journal:  Oncol Lett       Date:  2018-05-08       Impact factor: 2.967

6.  Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin α(v)β(3)-Targeted Radiotracer( 99m)Tc-3P-RGD(2).

Authors:  Yang Zhou; Guoqiang Shao; Shuang Liu
Journal:  Theranostics       Date:  2012-06-05       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.